Results 21 to 30 of about 57 (55)

Construction and verification of a quantitative index system to evaluate the medical and nursing care for the elderly service needs. [PDF]

open access: yesZhong Nan Da Xue Xue Bao Yi Xue Ban, 2023
Li F   +7 more
europepmc   +1 more source

[Clinical efficacy of combined therapy in children with stage 4 neuroblastoma]. [PDF]

open access: yesZhongguo Dang Dai Er Ke Za Zhi, 2022
Liang WL   +16 more
europepmc   +1 more source

[Infectious complications following chimeric antigen receptor T-cell therapy for a hematologic malignancy within 28 days]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi, 2021
Li YN   +7 more
europepmc   +1 more source

[Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)]. [PDF]

open access: yesZhonghua Gan Zang Bing Za Zhi, 2022
Chinese Society of Hepatology   +3 more
europepmc   +1 more source

[Expert consensus on the diagnosis and treatment of intrahepatic cholestasis (2021 edition)]. [PDF]

open access: yesZhonghua Gan Zang Bing Za Zhi, 2022
National Center for Clinical Research of Infectious Diseases.
europepmc   +1 more source

[The consensus on tertiary prevention of primary liver cancer (2022 version)]. [PDF]

open access: yesZhonghua Gan Zang Bing Za Zhi, 2022
Chinese Society of Hepatology   +1 more
europepmc   +1 more source

[Guidelines for the diagnosis and treatment of hepatolenticular degeneration (2022 edition)]. [PDF]

open access: yesZhonghua Gan Zang Bing Za Zhi, 2022
Inherited Metabolic Liver Disease Collaboration Group   +2 more
europepmc   +1 more source

"Mysterious veil" between the blood group system and pathogens. [PDF]

open access: yesZhong Nan Da Xue Xue Bao Yi Xue Ban, 2021
Ou C, Tian Y, Liang K, He J.
europepmc   +1 more source

[Clinical Practice and Quality Control Guidelines for Totally Implantable Venous Access Ports in Cancer Patients (2024)]. [PDF]

open access: yesSichuan Da Xue Xue Bao Yi Xue Ban
Professional Committee Of Interventional Oncology Chinese Anti-Cancer A   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy